PARAMUS, N.J., July 26, 2023 – Octapharma USA today announced that Balfaxar ® (prothrombin complex concentrate, human-lans; marketed in Europe and Canada as octaplex ®) has received U.S. Food and Drug ...
PARAMUS, N.J., April 2, 2025 /PRNewswire/ -- Octapharma USA announced the Journal of the American Medical Association (JAMA) has published results from a Phase III clinical trial, which observed ...
CSL Behring announced that the FDA has accepted for standard review its Biologics License Application (BLA) for a human 4-factor prothrombin complex concentrate (PCC) for the urgent reversal of ...
Among over 300 patients with the highest trauma level activation, the absolute difference in median total 24-hour blood product consumption between the 4F-PCC and placebo groups was 0.2 U (95% CI ...
Critical Care Product Portfolio to be Highlighted During American Society of Anesthesiologists Medical Congress in San Francisco PARAMUS, N.J., Oct. 10, 2023 /PRNewswire/ -- Octapharma USA will ...
About The Study: In this unblinded randomized clinical trial, prothrombin complex concentrate had superior hemostatic efficacy and safety advantages to frozen plasma among patients requiring ...
PARAMUS, N.J., April 2, 2025 /PRNewswire/ -- Octapharma USA announced the Journal of the American Medical Association (JAMA) has published results from a Phase III clinical trial, which observed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback